赛伦生物(688163.SH)：2025年度净利润5171.35万元，同比增长16.76%

Core Viewpoint - Sirun Biologics (688163.SH) reported a slight increase in total revenue for the fiscal year 2025, with a notable growth in net profit driven by various factors including reduced non-recurring losses and lower R&D expenses [1] Financial Performance - The company achieved total operating revenue of 196.21 million yuan, representing a year-on-year increase of 0.66% [1] - Operating profit reached 62.04 million yuan, up 19.34% year-on-year [1] - Total profit amounted to 61.74 million yuan, reflecting a year-on-year growth of 22.10% [1] - Net profit attributable to shareholders was 51.71 million yuan, showing a year-on-year increase of 16.76% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 42.56 million yuan, which is a significant increase of 50.65% year-on-year [1] Revenue and Market Contribution - The company's revenue showed a slight increase, while the gross profit margin remained stable [1] - The anti-rabies serum, which was listed in the second half of 2025, has not yet made a significant contribution to revenue during the reporting period [1] Factors Influencing Profit Growth - The increase in net profit is primarily attributed to the recognition of investment losses in the associate company Shanghai Saiyuan Biotechnology Co., Ltd. in 2024, full impairment of long-term equity investment balances, a decrease in non-recurring gains and losses, and a reduction in R&D expenses [1]